



## Summary of antimicrobial prescribing guidance – managing common infections

- See the British National Formulary (BNF) for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breastfeeding.
- See the TARGET antibiotics toolkit Summary of antimicrobial guidance page for accessible text summaries of the tables and links to full guidance.



| Infection             | Key points  | Medicine   | Doses   |  | Length        | Visual   |
|-----------------------|---|--|---|--|---------------|--|
| IIIIection            | Key points  | Medicille  | Adult   | Child  | Length        | summary  |
| Upper resp            | piratory tract infections   |  |   |  |               |  |
| Acute sore<br>throat  | Advise paracetamol, or if preferred and suitable, ibuprofen for pain.   | First choice:<br>phenoxymethylpenicillin                                     | 500mg QDS or<br>1000mg BD                         |  | 5 to 10 days* |  |
| NICE                  | Medicated lozenges may help pain in adults.<br>Use <u>FeverPAIN</u> or <u>Centor</u> to assess symptoms:  | Penicillin allergy:<br>clarithromycin OR                                     | 250mg to 500mg<br>BD                              |  | 5 days        |  |
| UK Health<br>Security | FeverPAIN 0-1 or Centor 0-2: no antibiotic;<br>FeverPAIN 2-3: no or back-up antibiotic;<br>FeverPAIN 4-5 or Centor 3-4: immediate or<br>back-up antibiotic. | erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm) | 250mg to 500mg<br>QDS or<br>500mg to 1000mg<br>BD | Bit         Descent of all           Image: Section of all of a | 5 days        | The first local product product of the second product of the secon |
| Agency                | Systemically very unwell or high risk of<br>complications: immediate antibiotic.  |  |   |  |               |  |
| Last updated:         | *5 days of phenoxymethylpenicillin may be enough for<br>symptomatic cure; but a 10-day course may increase<br>the chance of microbiological cure.           |  |   |  |               |  |
| Feb 2023              | For detailed information click the visual summary icon.   |  |   |  |               |  |

| Infection                               | Key points  | Medicine   | Doses                    |  | Length           | Visual                                   |
|---|---|--|--------------------------|--|------------------|--|
| mection                                 |   | Medicine   | Adult                    | Child  | Length           | summary                                  |
| Influenza<br>Last updated:<br>June 2023 | For management guidance please refer to UKHS  | <u>A guidance on Influenza: treat</u>  | ment and prophylaxis     | using ant  | ti-viral agents. |  |
| Status: Under review                    |   |  |                          |  |                  |  |
| Acute otitis                            | Regular paracetamol or ibuprofen for pain (right  | First choice: amoxicillin  | -                        |  | 5 to 7 days      |  |
| media                                   | dose for age or weight at the right time and maximum doses for severe pain).  | Penicillin allergy:<br>clarithromycin OR                                     | -                        |  | 5 to 7 days      |  |
| NICE                                    | Consider ear drops containing an anaesthetic<br>and an analgesic for pain if an immediate<br>antibiotic is not given and there is no ear drum<br>perforation or otorrhoea.        | erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm) | -                        |  |                  | Criss meta jacké antiniotálaj procho sec |
| UK Health<br>Security<br>Agency         | Otorrhoea or under 2 years with infection in both ears: no, back-up or immediate antibiotic.  | Second choice:<br>co-amoxiclav   | -                        | Control Development of the second sec | 5 to 7 days      |  |
| Last updated: Mar<br>2022               | Otherwise: no or back-up antibiotic.<br>Systemically very unwell or high risk of<br>complications: immediate antibiotic.<br>For detailed information click on the visual summary. |  |                          |  |                  |  |
| Acute otitis                            |   |  |                          | 1  | 1                |  |
| externa                                 | For management guidance please refer to NICE/0  | Clinical Knowledge Summaries   | s: <u>Otitis externa</u> |  |                  |  |
| Last updated:<br>June 2023              |   |  |                          |  |                  |  |
| Status: Under review                    |   |  |                          |  |                  |  |
|   |   |  |                          |  |                  |  |

| Infontion  | Key points   | Medicine  | Doses                                      | Doses  |                        | Visual  |
|--|--|---|--|--|------------------------|---|
| Infection  |  |   | Adult                                      | Child  | Length                 | summary   |
| Scarlet fever<br>(GAS)<br>Last updated:<br>June: 2023<br>Status: Under<br>review | For management guidance please refer to NICE/0   | Clinical Knowledge Summarie   | s: <u>Scarlet Fever</u>                    |  |                        |   |
| Sinusitis  | Advise paracetamol or ibuprofen for pain. Little evidence that nasal saline or nasal   | First choice:<br>phenoxymethylpenicillin  | 500mg QDS                                  |  | 5 days                 |   |
| NICE   | decongestants help, but people may want to try<br>them.<br>Symptoms for 10 days or less: no antibiotic.  | Penicillin allergy:<br>doxycycline (not in under<br>12s) OR   | 200mg on day 1,<br>then 100mg OD           |  | 5 days                 |   |
| INICL  | Symptoms with no improvement for more  | clarithromycin <b>OR</b>  | 500mg BD                                   |  |                        | Sinusits (scatch antimicrobial prescribing with |
| UK Health<br>Security  | <ul> <li>than 10 days: no antibiotic or back-up antibiotic depending on likelihood of bacterial cause. Consider high-dose nasal corticosteroid (if over 12 years).</li> <li>Systemically very unwell or high risk of complications: immediate antibiotic. For detailed information click on the visual summary.</li> </ul> | erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm)                                      | 250 to 500mg<br>QDS or<br>500 to 1000mg BD | Max         Descent and the second secon |                        |   |
| Agency<br>Last updated:<br>Oct 2017  |  | Second choice or first<br>choice if systemically<br>very unwell or high risk<br>of complications:<br>co-amoxiclay | 500/125mg TDS                              | -  | 5 days                 | _   |
| ▼ Lower res  | piratory tract infections  |   |  |  |                        |   |
| COVID-19   | Antibiotics should not be used for preventing or tro<br>Do not use azithromycin to treat COVID-19.   | eating COVID-19 unless there  | e is clinical suspicion o                  | f addition   | al bacterial co-infect | ion.  |
| NICE   | Do not use doxycycline to treat COVID-19 in the o  | community.  |  |  |                        |   |
| INICE  | Do not offer an antibiotic for preventing secondary  | •   | le with COVID-19.                          |  |                        |   |
| Last updated:<br>December 2021   | If a person in the community has suspected or co<br><u>community-acquired pneumonia</u> for choices.   |   |  | otic treatr  | nent as soon as pos    | sible, see                                      |
|  | In hospital, start empirical antibiotics if there is clir<br><u>pneumonia</u> for choices. Start antibiotics as soon a<br>4 hours. Start treatment within 1 hour if the person<br><u>guideline on sepsis</u> .   | as possible after establishing  | a diagnosis of seconda                     | ary bacter   | ial pneumonia, and     | certainly within                                |
|  | For detailed information, see the <u>NICE guideline on ma</u>  | naging COVID-19   |  |  |                        |   |

| Infontion                        | Kov points   | Medicine   | Doses   |       | Longth | Visual   |
|----------------------------------|--|--|---|-------|--------|--|
| Infection                        | Key points   | weatche  | Adult   | Child | Length | summary  |
| Acute<br>exacerbation<br>of COPD | <ul> <li>infections so will not respond to antibiotics.<br/>Consider an antibiotic, but only after taking into account severity of symptoms (particularly sputum colour changes and increases in volume or thickness), need for hospitalisation, previous exacerbations, hospitalisations and risk of complications, previous sputum culture and susceptibility results, and risk of resistance with repeated courses</li> </ul> | First choice:<br>amoxicillin OR  | 500mg TDS (see<br>BNF for severe<br>infection)                        | -     | 5 days |  |
| NICE                             |  | doxycycline <b>OR</b>  | 200mg on day 1,<br>then 100mg OD<br>(see BNF for<br>severe infection) | -     |        |  |
|                                  |  | clarithromycin   | 500mg BD  | -     |        |  |
| UK Health                        |  | Second choice: use alternative first choice  |   |       |        | COPO-Luce successful data in the last state and a stat |
| Security<br>Agency               | Some people at risk of exacerbations may have<br>antibiotics to keep at home as part of their<br>exacerbation action plan.   | Alternative choice (if<br>person at higher risk of<br>treatment failure):                                    | 500/125mg TDS   | -     |        |  |
|                                  | For detailed information click on the visual summary.  | co-amoxiclav OR  |   |       | -      |  |
| Last updated:                    | See also the <u>NICE guideline on COPD in over 16s</u> .   | co-trimoxazole <b>OR</b>   | 960mg BD  | -     | 5 days |  |
| September 2024                   | September 2024<br>* See the <u>MHRA January 2024 advice</u> on restrictions<br>and precautions for using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-   | levofloxacin* (only if other<br>alternative choice<br>antibiotics are unsuitable;<br>with specialist advice) | 500mg OD  | -     |        |  |
|                                  | lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly<br>recommended antibiotics are inappropriate.  | IV antibiotics (click on visu  | al summary)   |       |        |  |

| Infection                                     | Kov pointo  | Madiaina  | Doses                            |       |              | Visual  |
|---|---|---|----------------------------------|-------|--------------|---|
| Infection                                     | Key points  | Medicine  | Adult                            | Child | Length       | summary   |
| Acute<br>exacerbation<br>of<br>bronchiectasis | erbationsusceptibility testing.trchiectasiscysticsis)   | First choice empirical<br>treatment:<br>amoxicillin (preferred if<br>pregnant) OR                                   | 500mg TDS                        |       | 7 to 14 days |   |
| (non-cystic<br>fibrosis)                      |   | doxycycline (not in under 12s) <b>OR</b>  | 200mg on day 1,<br>then 100mg OD |       |              |   |
|   |   | clarithromycin  | 500mg BD                         |       |              |   |
| <b>NICE</b><br>UK Health                      | repeated courses of antibiotics, a previous<br>sputum culture with resistant or atypical<br>bacteria, or a higher risk of developing<br>complications.<br>Course length is based on severity of<br>bronchiectasis, exacerbation history, severity of<br>exacerbation symptoms, previous culture and<br>susceptibility results, and response to treatment. | Alternative choice (if<br>person at higher risk of<br>treatment failure)<br>empirical treatment:<br>co-amoxiclav OR | 500/125mg TDS                    |       | 7 to 14 days |   |
| Security<br>Agency                            |   | levofloxacin* (adults only:<br>only if co-amoxiclav is<br>unsuitable; with specialist<br>advice) <b>OR</b>          | 500mg OD or BD                   |       |              | Reference       Reference |
| Last updated:<br>September 2024               | prevent exacerbations.<br>Seek specialist advice for preventing<br>exacerbations in people with repeated acute<br>exacerbations. This may include a trial of  | ciprofloxacin* (children<br>only: only if co-amoxiclav<br>is unsuitable; with<br>specialist advice)                 | -                                |       |              |   |
|   | antibiotic prophylaxis after a discussion of the possible benefits and harms, and the need for  | IV antibiotics (click on visu   |                                  |       |              |   |
|   | regular review.   | When current susceptibili   |                                  |       |              |   |
|   | For detailed information click on the visual summary.   |   |                                  |       |              |   |
|   | * See the <u>MHRA January 2024 advice</u> on restrictions<br>and precautions for using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly<br>recommended antibiotics are inappropriate.                   |   |                                  |       |              |   |

| Infection          | Kou pointo   | Medicine  | Doses                            |       | Longth | Visual  |
|--------------------|--|---|----------------------------------|-------|--------|---------|
| Intection          | Key points   | weatcine  | Adult                            | Child | Length | summary |
| Acute cough        | Some people may wish to try honey (in over 1s), the herbal medicine pelargonium (in over 12s),   | Adults first choice:<br>doxycycline   | 200mg on day 1,<br>then 100mg OD | -     |        |         |
| NICE               | guaifenesin (in over 12s) or cough medicines<br>containing cough suppressants, except codeine,<br>(in over 12s). These self-care treatments have<br>limited evidence for the relief of cough   | Adults alternative first<br>choices:<br>amoxicillin (preferred if<br>pregnant) OR | 500mg TDS                        | -     |        |         |
| UK Health          | symptoms.  | clarithromycin <b>OR</b>  | 250mg to 500mg<br>BD             | -     | 5 days |         |
| Security<br>Agency | Acute cough with upper respiratory tract infection: no antibiotic.   | erythromycin (if macrolide needed in pregnancy;                                   | 250mg to 500mg<br>QDS or         |       |        |         |
| Last updated:      | Acute bronchitis: no routine antibiotic.<br>Acute cough and higher risk of   | consider benefit/harm)  | 500mg to 1000mg<br>BD            | -     |        |         |
| Feb 2019           | complications (at face-to-face examination): immediate or back-up antibiotic.  | Children first choice:<br>amoxicillin   | -                                |       |        |         |
|                    | Acute cough and systemically very unwell (at face to face examination): immediate antibiotic.  |   |                                  |       |        |         |
|                    | Higher risk of complications includes people with pre-existing comorbidity; young children born  | erythromycin <b>OR</b>  | -                                |       |        |         |
|                    | pre-existing comobility, young children born<br>prematurely; people over 65 with 2 or more of,<br>or over 80 with 1 or more of: hospitalisation in<br>previous year, type 1 or 2 diabetes, history of<br>congestive heart failure, current use of oral<br>corticosteroids. | doxycycline (not in under<br>12s)   | -                                |       | 5 days |         |
|                    | Do not offer a mucolytic, an oral or inhaled<br>bronchodilator, or an oral or inhaled<br>corticosteroid unless otherwise indicated.  |   |                                  |       |        |         |
|                    | For detailed information click on the visual summary.  |   |                                  |       |        |         |

| Infection                          | Kowneinte  | Madiaina  | Doses  |       | L on oth              | Visual   |
|------------------------------------|--|---|--|-------|-----------------------|--|
| Infection                          | Key points   | Medicine  | Adult  | Child | Length                | summary  |
| Hospital-<br>acquired<br>pneumonia | If symptoms or signs of pneumonia start within<br>48 hours of hospital admission, see <u>community</u><br><u>acquired pneumonia</u> .<br>Offer an antibiotic. Start treatment as soon as                           | First choice (non-severe<br>and not higher risk of<br>resistance):<br>co-amoxiclav  | 500/125 mg TDS   |       | 5 days then review    |  |
| NICE                               | possible after diagnosis, within 4 hours (within<br>1 hour if sepsis suspected and person meets<br>any high risk criteria – see the <u>NICE guideline</u><br><u>on sepsis</u> ).                                   | Adults alternative first<br>choice (non-severe and<br>not higher risk of<br>resistance)                                       | 200mg on day 1,<br>then 100mg OD                                 |       |                       |  |
| UK Health<br>Security<br>Agency    | When choosing an antibiotic, take account of severity of symptoms or signs, number of days in hospital before onset of symptoms, risk of   | Choice based on specialist<br>microbiological advice and<br>local resistance data   |  | -     |                       |  |
| Last updated:                      | developing complications, local hospital and<br>ward-based antimicrobial resistance data, recent   | Options include:<br>doxycycline   |  |       |                       |  |
| September 2024                     | antibiotic use and microbiological results, recent<br>contact with a health or social care setting<br>before current admission, and risk of adverse<br>effects with broad spectrum antibiotics.                    | cefalexin (caution in penicillin allergy)   | 500 mg BD or TDS<br>(can increase to<br>1 to 1.5g TDS or<br>QDS) | -     | 5 days then<br>review | Process of containing and containing |
|                                    | No validated severity assessment tools are<br>available. Assess severity of symptoms or signs<br>based on clinical judgement.  | co-trimoxazole  | 960mg BD   | -     |                       |  |
|                                    | Higher risk of resistance includes relevant<br>comorbidity (such as severe lung disease or<br>immunosuppression), recent use of broad<br>spectrum antibiotics, colonisation with multi-drug                        | levofloxacin* (only if<br>switching from IV<br>levofloxacin with specialist<br>advice)  | 500mg OD or BD   | -     | -                     |  |
|                                    | resistant bacteria, and recent contact with health<br>and social care settings before current<br>admission.  | Children alternative first<br>choice (non-severe and<br>not higher risk of  | -  |       |                       |  |
|                                    | If symptoms or signs of pneumonia start within<br>days 3 to 5 of hospital admission in people not<br>at higher risk of resistance, consider following<br>community acquired pneumonia for choice of<br>antibiotic. | resistance):<br>clarithromycin<br>Other options may be<br>suitable based on<br>specialist microbiological<br>advice and local |  |       | -                     |  |
|                                    | For detailed information click on the visual summary.  | resistance data   |  |       |                       |  |

| Infection                           | Key points   | Madiaina   | Doses   |       |         | Visual  |
|-------------------------------------|--|--|---|-------|---------|---------|
| Infection                           |  | Medicine   | Adult   | Child | Length  | summary |
|                                     | *See the <u>MHRA January 2024 advice</u> on restrictions<br>and precautions for using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly<br>recommended antibiotics are inappropriate. | For first choice IV antibiot<br>antibiotics to be added if s<br>visual summary   |   |       |         |         |
| Community-<br>acquired<br>pneumonia | Assess severity in adults based on clinical<br>judgement and guided by a mortality risk score<br>(CRB65 or CURB65) when these scores can be<br>calculated:   | First choice (low severity<br>in adults or non-severe<br>in children):<br>amoxicillin                                      | 500mg TDS<br>(higher doses can<br>be used, see BNF) |       |         |         |
| NICE                                | low severity – CRB65 0 or CURB65 0 or 1<br>moderate severity – CRB65 1 or 2 or CURB65<br>2<br>high severity – CRB65 3 or 4 or CURB65 3 to  | Alternative first choice<br>(low severity in adults or<br>non-severe in children):<br>doxycycline (not in under<br>12s) OR | 200mg on day 1,<br>then 100mg OD                    |       | 5 days* |         |
| UK Health<br>Security<br>Agency     | 5.<br>1 point for each parameter: <b>confusion</b> , ( <b>urea</b><br>>7 mmol/l), <b>respiratory rate</b> ≥30/min, low<br>systolic (<90 mm Hg) or diastolic (≤60 mm Hg)  | clarithromycin <b>OR</b><br>erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm)                   | 500mg BD<br>500mg QDS                               | -     |         |         |
| Last updated:<br>September 2024     | <ul> <li>blood pressure, age ≥65.</li> <li>Assess severity in children based on clinical judgement.</li> <li>Offer an antibiotic. Start treatment as soon as possible after diagnosis, within 4 hours (within</li> </ul>   | First choice (moderate<br>severity in adults):<br>amoxicillin<br>AND (if atypical<br>pathogens suspected)                  | 500mg TDS<br>(higher doses can<br>be used, see BNF) | -     |         |         |
|                                     | 1 hour if sepsis suspected and person meets<br>any high risk criteria – see the <u>NICE guideline</u><br>on sepsis).   | clarithromycin <b>OR</b><br>erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm)                   | 500mg BD<br>500mg QDS                               | -     | 5 days* |         |
|                                     | When choosing an antibiotic, take account of severity, risk of complications, local antimicrobial resistance and surveillance data, recent antibiotic use and microbiological results. <i>For detailed information click on the visual summary.</i>  | Alternative first choice<br>(moderate severity in<br>adults):<br>doxycycline OR  | 200mg on day 1,<br>then 100mg OD                    | -     |         |         |
|                                     | For detailed information click on the visual summary.  | clarithromycin   | 500mg BD  | -     |         |         |

| Infection | Kov points   | Medicine   | Doses                                  |       | Length  | Visual  |
|-----------|--|--|--|-------|---------|---------|
| Intection | Key points   | Medicine   | Adult                                  | Child | Lengin  | summary |
|           | *Stop antibiotics after 5 days unless microbiological<br>results suggest a longer course is needed or the<br>person is not clinically stable.<br>**See the <u>MHRA January 2024 advice</u> on restrictions<br>and precautions for using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. | First choice (high<br>severity in adults or<br>severe in children):<br>co-amoxiclav<br>AND (if atypical<br>pathogens suspected)<br>clarithromycin OR<br>erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm) | 500/125mg TDS<br>500mg BD<br>500mg QDS |       | 5 days* |         |
|           |  | Alternative antibiotic if<br>high severity, for<br>penicillin allergy:<br>levofloxacin**   | 500mg BD                               | -     |         |         |
|           |  | IV antibiotics (click on visua   | al summary)                            |       |         |         |

| Infection                     | Key points   | Medicine  | Doses   |       | Length      | Visual   |
|-------------------------------|--|---|---|-------|-------------|--|
|                               |  | weatchie  | Adult   | Child | Lengin      | summary  |
| ▼ Urinary tra                 | act infections   |   |   |       |             |  |
| Lower urinary tract infection | Advise paracetamol or ibuprofen for pain.<br><b>Non-pregnant women</b> : back up antibiotic (to<br>use if no improvement in 48 hours or symptoms<br>worsen at any time) or immediate antibiotic.   | Non-pregnant women<br>first choice:<br>nitrofurantoin (if eGFR<br>≥45 ml/minute) OR   | 100mg m/r BD (or<br>if unavailable<br>50mg QDS) | -     | 3 days      |  |
| NICE                          | Pregnant women, men, children or young people: immediate antibiotic.   | trimethoprim (if low risk of resistance)  | 200mg BD  | -     |             |  |
| UK Health<br>Security         | When considering antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to  | Non-pregnant women<br>second choice:<br>nitrofurantoin (if eGFR<br>≥45 ml/minute) OR  | 100mg m/r BD (or<br>if unavailable<br>50mg QDS) | -     | 3 days      |  |
| Agency                        | resistant bacteria and local antimicrobial resistance data.  | pivmecillinam (a penicillin) <b>OR</b>  | 400mg initial dose,<br>then 200mg TDS           | -     | 3 days      |  |
| Last updated:<br>Oct 2018     | If people have symptoms of pyelonephritis (such as fever) or a complicated UTI, see <u>acute</u>   | fosfomycin  | 3g single dose sachet                           | -     | single dose |  |
| Oct 2018                      | pyelonephritis (upper urinary tract infection) for<br>antibiotic choices.<br>For detailed information click on the visual summary.<br>See also the <u>NICE guideline on urinary tract infection</u><br>in under 16s: diagnosis and management and the UK | Pregnant women first<br>choice: nitrofurantoin<br>(avoid at term) – if eGFR<br>≥45 ml/minute                                    | 100mg m/r BD (or<br>if unavailable<br>50mg QDS) | -     | 7 days      | 10 and shares shift provides the second states of t |
|                               | Health Security Agency <u>urinary tract infection:</u><br><u>diagnostic tools for primary care</u> .   | <b>Pregnant women second</b><br><b>choice</b> : amoxicillin (only if<br>culture results available<br>and susceptible) <b>OR</b> | 500mg TDS                                       | -     | 7 days      |  |
|                               |  | cefalexin   | 500mg BD  | -     |             |  |
|                               |  | Treatment of asymptomatinitrofurantoin (avoid at term)<br>and susceptibility results  |   |       |             |  |
|                               |  | Men first choice:<br>trimethoprim OR  | 200mg BD  | -     |             |  |
|                               |  | nitrofurantoin (if eGFR<br>≥45 ml/minute)   | 100mg m/r BD (or<br>if unavailable<br>50mg QDS) | -     | 7 days      |  |

| Infection | Kov pointo | Medicine   | Doses |       | Longth | Visual  |  |
|-----------|------------|--|-------|-------|--------|---------|--|
| Infection | Key points | weatche  | Adult | Child | Length | summary |  |
|           |            | <b>Men second choice</b> : consider alternative diagnoses basing antibiotic choice on recent culture and susceptibility results                    |       |       |        |         |  |
|           |            | Children and young<br>people (3 months and<br>over) first choice:<br>trimethoprim (if low risk of<br>resistance) OR                                | -     |       |        |         |  |
|           |            | nitrofurantoin (if eGFR<br>≥45 ml/minute)  | -     |       |        |         |  |
|           |            | Children and young<br>people (3 months and<br>over) second choice:<br>nitrofurantoin (if eGFR<br>≥45 ml/minute and not<br>used as first choice) OR | -     |       | -      |         |  |
|           |            | amoxicillin (only if culture<br>results available and<br>susceptible) <b>OR</b>  | -     |       |        |         |  |
|           |            | cefalexin  | -     |       |        |         |  |

| Infection   | Koy points   | Madiaina  | Doses  |             |                    | Visual  |
|---|--|---|--|-------------|--------------------|---------|
| Infection   | Key points   | Medicine  | Adult  | Child       | Length             | summary |
| Acute<br>pyelonephritis<br>(upper urinary<br>tract) | for pain for people over 12.<br>Offer an antibiotic.<br>When prescribing antibiotics, take account of<br>severity of symptoms, risk of complications,<br>previous urine culture and susceptibility results,<br>previous antibiotic use which may have led to<br>resistant bacteria and local antimicrobial<br>resistance data.<br>Avoid antibiotics that don't achieve adequate<br>levels in renal tissue, such as nitrofurantoin. | Non-pregnant women<br>and men first choice:<br>cefalexin OR                       | 500mg BD or TDS<br>(up to 1g to 1.5g<br>TDS or QDS for<br>severe infections) | -           | 7 to 10 days       |         |
| NICE  |  | co-amoxiclav (only if<br>culture results available<br>and susceptible) <b>OR</b>  | 500/125mg TDS  | -           | 7 to 10 days       | -       |
|   |  | trimethoprim (only if<br>culture results available<br>and susceptible) <b>OR</b>  | 200mg BD   | -           | 14 days            | -       |
| UK Health<br>Security<br>Agency                     | For detailed information click on the visual summary.<br>See also the <u>NICE guideline on urinary tract infection</u><br><u>in under 16s: diagnosis and management</u> and the UK<br>Health Security Agency <u>urinary tract infection</u> :  | ciprofloxacin* (only if other<br>first-choice antibiotics are<br>unsuitable)      | 500mg BD   | -           | 7 days             |         |
|   | diagnostic tools for primary care.   | Non-pregnant women and  |  |             |                    |         |
| Last updated:<br>September 2024                     | ast updated: *See the MHPA Jonuany 2024 eduice on metrictions  | Pregnant women first<br>choice:<br>cefalexin                                      | 500mg BD or TDS<br>(up to 1g to 1.5g<br>TDS or QDS for<br>severe infections) | -           | 7 to 10 days       |         |
|   | lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly  | Pregnant women second of  | choice or IV antibioti   | cs (click   | on visual summary) |         |
|   | recommended antibiotics are inappropriate.   | Children and young<br>people (3 months and<br>over) first choice:<br>cefalexin OR | -  |             | -                  | -       |
|   |  | co-amoxiclav (only if<br>culture results available<br>and susceptible)            | -  |             |                    |         |
|   |  | Children and young peopl visual summary)  | e (3 months and ove  | er) IV anti | biotics (click on  |         |

| Infontion                               | Key points  | Medicine  | Doses  |       | Longth              | Visual  |
|---|---|---|--|-------|---------------------|---------|
| Infection                               |   | weatcine  | Adult  | Child | Length              | summary |
| Acute<br>prostatitis                    | Advise paracetamol (+/- low-dose weak opioid)<br>for pain, or ibuprofen if preferred and suitable.<br>Offer antibiotic.   | First choice (guided by<br>susceptibilities when<br>available):<br>ciprofloxacin* <b>OR</b> | 500mg BD   | -     |                     |         |
|   | Review antibiotic treatment after 14 days and either stop antibiotics or continue for a further   | ofloxacin* OR   | 200mg BD   | -     | -                   |         |
| NICE<br>UK Health                       | 14 days if needed (based on assessment of<br>history, symptoms, clinical examination, urine<br>and blood tests).<br>For detailed information click on the visual summary  | Alternative first choice if<br>fluoroquinolone<br>antibiotic is not<br>appropriate (seek    | 200mg BD   | -     | 14 days then review |         |
| Security<br>Agency                      | * See the <u>MHRA January 2024 advice</u> on restrictions<br>and precautions for using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. | specialist advice; guided<br>by susceptibilities when<br>available):<br>trimethoprim        |  |       |                     |         |
| Last updated:<br>September 2024         |   | Second choice (after<br>discussion with specialist):<br>levofloxacin* OR                    | 500mg OD   | -     | 14 days then review |         |
|   |   | co-trimoxazole  | 960mg BD   | -     |                     |         |
|   |   | IV antibiotics (click on visu   | al summary)  |       |                     |         |
| Recurrent<br>urinary tract<br>infection | First advise about behavioural and personal hygiene measures, and self-care (with D-mannose or cranberry products) to reduce the risk of UTI.   | First choice antibiotic<br>prophylaxis: trimethoprim<br>(avoid in pregnancy) OR             | 200mg single dose<br>when exposed to a<br>trigger or<br>100mg at night |       | -                   |         |

| Infection                       | Kov points   | Medicine   | Doses   |   | Length | Visual  |
|---------------------------------|--|--|---|---|--------|---------|
| infection                       | Key points   | Medicine   | Adult   | Child   | Length | summary |
| NICE                            | For postmenopausal women, if no improvement,<br>consider vaginal oestrogen (review within<br>12 months).<br>For non-pregnant women, if no improvement,<br>consider single-dose antibiotic prophylaxis for  | nitrofurantoin (avoid at<br>term) - if eGFR<br>≥45 ml/minute | 100mg single dose<br>when exposed to a<br>trigger or<br>50 to 100mg at<br>night | March         March and March           Status         Status         Status   | -      |         |
| UK Health<br>Security<br>Agency | exposure to a trigger (review within 6 months).<br>For non-pregnant women (if no improvement or<br>no identifiable trigger) or with specialist advice<br>for pregnant women, men, children or young  | Second choice antibiotic<br>prophylaxis:<br>amoxicillin OR   | 500mg single dose<br>when exposed to a<br>trigger or<br>250mg at night          | Sector         Manual Anna Carlos           Sector         Sector         Sector   | -      |         |
| Last updated Oct<br>2018        | people, consider a trial of daily antibiotic<br>prophylaxis (review within 6 months).<br>For detailed information click on the visual summary.<br>See also the <u>NICE guideline on urinary tract infection</u><br><u>in under 16s: diagnosis and management</u> and the UK<br>Health Security Agency <u>urinary tract infection</u> :<br><u>diagnostic tools for primary care</u> . | cefalexin  | 500mg single dose<br>when exposed to a<br>trigger or<br>125mg at night          | Image: Control of the second | -      |         |

| Infontion   | Kov pointo   | Madiaina  | Doses  |           | Longth                 | Visual   |
|---|--|---|--|-----------|------------------------|--|
| Infection   | Key points   | Medicine  | Adult  | Child     | Length                 | summary  |
| Catheter-<br>associated<br>urinary tract<br>infection | <ul> <li>asymptomatic bacteriuria in people with a urinary catheter.</li> <li>Consider removing or, if not possible, changing the catheter if it has been in place for more than 7 days. But do not delay antibiotic treatment.</li> <li>Advise paracetamol for pain.</li> <li>Advise drinking enough fluids to avoid dehydration.</li> <li>Offer an antibiotic for a symptomatic infection.</li> <li>When prescribing antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria and local antimicrobial resistance data.</li> <li>Do not routinely offer antibiotic prophylaxis to people with a short-term or long-term catheter.</li> </ul> | Non-pregnant women<br>and men first choice if<br>no upper UTI symptoms:<br>nitrofurantoin (if eGFR ≥45<br>ml/minute) OR | 100mg m/r BD (or<br>if unavailable<br>50mg QDS)                              | -         | 7 40.0                 |  |
|   |  | trimethoprim (if low risk of resistance) <b>OR</b>  | 200mg BD   | -         | 7 days                 |  |
| NICE  |  | amoxicillin (only if culture<br>results available and<br>susceptible)   | 500mg TDS  | -         | -                      |  |
| UK Health<br>Security<br>Agency                       |  | Non-pregnant women<br>and men second choice<br>if no upper UTI<br>symptoms:<br>pivmecillinam (a penicillin)             | 400mg initial dose,<br>then 200mg TDS  | -         | 7 days<br>7 to 10 days |  |
| Last updated:<br>September 2024                       |  | Non-pregnant women<br>and men first choice if<br>upper UTI symptoms:<br>cefalexin OR                                    | 500mg BD or TDS<br>(up to 1g to 1.5g<br>TDS or QDS for<br>severe infections) | -         |                        | Unitadicate additional quantities of the second sec |
|   | For detailed information click on the visual summary.<br>See also the <u>UK Health Security Agency urinary tract</u><br><u>infection: diagnostic tools for primary care</u> .<br>*See the <u>MHRA January 2024 advice</u> for restrictions   | co-amoxiclav (only if<br>culture results available<br>and susceptible) <b>OR</b>  | 500/125mg TDS  | -         |                        |  |
|   | and precautions on using fluoroquinolone antibiotics<br>because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly  | trimethoprim (only if<br>culture results available<br>and susceptible) <b>OR</b>  | 200mg BD   | -         | 14 days                |  |
|   | recommended antibiotics are inappropriate.   | ciprofloxacin* (only if other<br>first-choice antibiotics are<br>unsuitable)  | 500mg BD   | -         | 7 days                 |  |
|   |  | Non-pregnant women and  |  |           |                        |  |
|   |  | Pregnant women first<br>choice:<br>cefalexin  | 500mg BD or TDS<br>(up to 1g to 1.5g<br>TDS or QDS for<br>severe infections) | -         | 7 to 10 days           |  |
|   |  | Pregnant women second of  | choice or IV antibioti   | cs (click | on visual summary)     |  |

| Infection                             | Key points                                     | Medicine                                     | Doses               | Doses  |                    | Visual  |
|---------------------------------------|--|--|---------------------|--|--------------------|---------|
| Intection                             | Key points                                     | weatchie                                     | Adult               | Child  | Length             | summary |
|                                       |  | Children and young                           | -                   |  |                    |         |
|                                       |  | people (3 months and<br>over) first choice:  |                     |  |                    |         |
|                                       |  | trimethoprim (if low risk of                 |                     |  |                    |         |
|                                       |  | resistance) OR                               |                     |  |                    |         |
|                                       |  | amoxicillin (only if culture                 | -                   | Address         National Address and Address           Scheller         In address and Addre   | _                  |         |
|                                       |  | results available and susceptible) <b>OR</b> |                     | Lines 2 - Constanting 2 - Cons |                    |         |
|                                       |  | cefalexin <b>OR</b>                          | -                   |  |                    |         |
|                                       |  | co-amoxiclav (only if                        | -                   |  |                    |         |
|                                       |  | culture results available and susceptible)   |                     |  |                    |         |
|                                       |  | Children and young people visual summary)    | e (3 months and ove | er) IV antil   | biotics (click on  |         |
| ▼ Meningitis                          |  |  |                     |  |                    |         |
| Suspected<br>meningococcal<br>disease | For management guidance please refer to Mening | gococcal disease: guidance on                | public health manag | ement - G  | OV.UK (www.gov.uk) | L       |
| Last updated:<br>June 2023            |  |  |                     |  |                    |         |
| Status: Under review                  |  |  |                     |  |                    |         |
| Prevention of                         |  |  |                     |  |                    |         |
| secondary<br>case of                  | For management guidance please refer to Mening | gococcal disease: guidance or                | public health manag | ement - G  | OV.UK (www.gov.uk) |         |
| meningitis                            |  |  |                     |  |                    |         |
| _                                     |  |  |                     |  |                    |         |
| Last updated:<br>June 2023            |  |  |                     |  |                    |         |
| Status: Under review                  |  |  |                     |  |                    |         |

| Infection   | Key points                                    | Medicine                     | Doses                        |              | Length              | Visual  |
|---|---|------------------------------|------------------------------|--------------|---------------------|---------|
| ▼ Gastrointe  | estinal tract infections                      |                              | Adult                        | Child        |                     | summary |
| Oral candidiasis  | For management guidance please refer to NICE/ | /Clinical Knowledge Summarie | es: <u>Candida oral</u>      |              |                     |         |
| Last updated:<br>June 2023                                |   |                              |                              |              |                     |         |
| Status: Under review                                      | · · ·   |                              |                              |              |                     |         |
| Infectious<br>diarrhoea<br>Last updated:<br>June 2023     | For management guidance please refer to NICE/ | Clinical Knowledge Summarie  | s: <u>Gastroenteritis</u>    |              |                     |         |
| Status: Under review                                      |   |                              |                              |              |                     |         |
| Traveller's<br>diarrhoea<br>Last updated:<br>June 2023    | For management guidance please refer to NICE/ | Clinical Knowledge Summarie  | s: <u>Diarrhoea - prever</u> | ntion and ad | vice for travellers |         |
| Status: Under review                                      |   |                              |                              |              |                     |         |
| Threadworm<br>Last updated:<br>June 2023<br>Status: Under | For management guidance please refer to NICE/ | Clinical Knowledge Summarie  | s: <u>Threadworm</u>         |              |                     |         |
| review  |   |                              |                              |              |                     |         |

| Infection  | Kourseinte   | Madiaina  | Doses     |                     | l on oth | Visual  |
|--|--|---|-----------|---------------------|----------|---------|
| Infection  | Key points   | Medicine  | Adult     | Child               | Length   | summary |
| Clostridioides<br>difficile<br>infection                     | For suspected or confirmed <i>C. difficile</i> infection,<br>see <u>UK Health Security Agency's guidance on</u><br><u>diagnosis and reporting</u> .  | First-line for first<br>episode of mild,<br>moderate or severe:   | 125mg QDS | BNF<br>for children |          |         |
| NICE   | <ul> <li>Assess: whether it is a first or further episode, severity of infection, individual risk factors for complications or recurrence (such as age, frailty or comorbidities).</li> <li>Existing antibiotics: review and stop unless essential. If still essential, consider changing to</li> </ul>  | vancomycin<br>Second-line for first<br>episode of mild,<br>moderate or severe if<br>vancomycin ineffective:     | 200mg BD  | BNF<br>for children | -        |         |
| UK Health<br>Security<br>Agency<br>Last updated:<br>Jul 2021 | one with a lower risk of <i>C. difficile</i> infection.<br>Review the need to continue: proton pump<br>inhibitors, other medicines with gastrointestinal<br>activity or adverse effects (such as laxatives),<br>medicines that may cause problems if people<br>are dehydrated (such as NSAIDs).  | fidaxomicin<br>For further episode<br>within 12 weeks of<br>symptom resolution<br>(relapse):<br>fidaxomicin     | 200mg BD  | BNF<br>for children | 10 days  |         |
|  | Do not offer antimotility medicines such as<br>loperamide.<br>Offer an oral antibiotic to treat suspected or<br>confirmed <i>C. difficile</i> infection.   | For further episode more<br>than 12 weeks after<br>symptom resolution<br>(recurrence):                          | 125mg QDS | BNF<br>for children |          |         |
|  | confirmed <i>C. difficile</i> infection.<br>For adults, consider seeking prompt specialist<br>advice from a microbiologist or infectious<br>diseases specialist before starting treatment.<br>For children and young people, treatment should<br>be started by, or after advice from, a<br>microbiologist, paediatric infectious diseases<br>specialist or paediatric gastroenterologist.<br>If antibiotics have been started for suspected<br><i>C. difficile</i> infection, and subsequent stool<br>sample tests do not confirm infection, consider<br>stopping these antibiotics.<br><i>For detailed information click on the visual summary.</i> | vancomycin OR<br>fidaxomicin<br>For alternative antibiotics<br>ineffective or for life-threa<br>visual summary) |           |                     |          |         |

| Infontion                               | Key points  | Medicine  | Doses   |             | Longth  | Visual   |
|---|---|---|---|-------------|---------|--|
| Infection                               |   |   | Adult   | Child       | Length  | summary  |
| Helicobacter<br>pylori                  | For management guidance please refer to NICE/E  | BNF treatment summaries: <u>He</u>  | licobacter pylori infec   | tion        |         |  |
| Last updated:<br>June 2023              |   |   |   |             |         |  |
| Status: Under<br>review                 |   |   |   |             |         |  |
| Acute<br>diverticulitis                 | Acute diverticulitis and systemically well:<br>Consider no antibiotics, offer simple analgesia<br>(for example paracetamol), advise to re-present<br>if symptoms persist or worsen.   | First-choice<br>(uncomplicated acute<br>diverticulitis):<br>co-amoxiclav  | 500/125mg TDS   | -           |         |  |
| NICE<br>Last updated:<br>September 2024 | Acute diverticulitis and systemically unwell,<br>immunosuppressed or significant<br>comorbidity: offer an antibiotic.<br>Give oral antibiotics if person not referred to<br>hospital for suspected complicated acute<br>diverticulitis.<br>Give IV antibiotics if admitted to hospital with | Penicillin allergy or<br>co-amoxiclav unsuitable:<br>cefalexin (caution in<br>penicillin allergy) AND<br>metronidazole OR | cefalexin: 500mg<br>BD or TDS (up to<br>1g to 1.5g TDS or<br>QDS for severe<br>infections)<br>metronidazole:<br>400mg TDS | -           | 5 days* |  |
|   | suspected or confirmed complicated acute<br>diverticulitis (including diverticular abscess).<br>If CT-confirmed uncomplicated acute<br>diverticulitis, review the need for antibiotics.   | trimethoprim <b>AND</b><br>metronidazole <b>OR</b>  | trimethoprim:<br>200mg BD<br>metronidazole:<br>400mg TDS  | -           |         | Church can discuss antibio stability and discuss antibio stability antib |
|   | <ul> <li>For detailed information click on the visual summary.</li> <li>* A longer course may be needed based on clinical assessment.</li> <li>** See the <u>MHRA January 2024</u> advice for restrictions and precautions on using fluoroquinolone antibiotics</li> </ul>                  | ciprofloxacin** (only if<br>switching from IV<br>ciprofloxacin with<br>specialist advice) <b>AND</b><br>metronidazole     | ciprofloxacin:<br>500mg BD<br>metronidazole:<br>400mg TDS   |             |         |  |
|   | because of the risk of disabling and potentially long-<br>lasting or irreversible side effects. Fluoroquinolones<br>must now only be prescribed when other commonly<br>recommended antibiotics are inappropriate.   | For IV antibiotics in comp<br>diverticular abscess) see   |   | culitis (in | cluding |  |
|   |   |   |   |             |         |  |

| Infection                               | Key points                                     | Medicine                      | Doses               |                | Length             | Visual  |
|---|--|-------------------------------|---------------------|----------------|--------------------|---------|
|   |  | medicine                      | Adult               | Child          | Length             | summary |
|   | act infections                                 |                               |                     |                |                    |         |
| Epididymitis                            | For management guidance please refer to the BA | SHH United Kingdom guidelin   | e for the manageme  | nt of Enididy  | mo-orchitis        |         |
| Last updated:<br>June 2023              | To management guidance please reler to the Dr  | Controllited Kingdom guidelin |                     |                |                    |         |
| Status: Under review                    |  |                               |                     |                |                    |         |
| Chlamydia<br>trachomatis/<br>urethritis | For management guidance please refer to the BA | ASHH United Kingdom guidelin  | ne for the manageme | nt of Chlamy   | <u>dia</u>         |         |
| Last updated:<br>June 2023              |  |                               |                     |                |                    |         |
| Status: Under review                    |  |                               |                     |                |                    |         |
| Vaginal<br>candidiasis                  | For management guidance please refer to the BA | SHH United Kingdom guidelin   | ne for the manageme | nt of Vulvova  | aginal candidiasis |         |
| Last updated:<br>June 2023              |  |                               |                     |                |                    |         |
| Status: Under review                    |  |                               |                     |                |                    |         |
| Bacterial<br>vaginosis                  | For management guidance please refer to the BA | SHH United Kingdom guidelin   | ne for the manageme | nt of Bacteria | al vaginosis       |         |
| Last updated:<br>June 2023              |  |                               |                     |                |                    |         |
| Status: Under review                    |  |                               |                     |                |                    |         |

| Infection                         | Kov points  | Key points Medicine Doses           |                             |               | Longth              | Visual    |
|-----------------------------------|---|-------------------------------------|-----------------------------|---------------|---------------------|-----------|
| Intection                         | Key points  | Wealchie                            | Adult                       | Child         | Length              | summary   |
| Genital herpes                    |   |                                     | <b>7</b> - 11               |               | 5 I I               |           |
| Last updated:<br>June 2023        | For management guidance please refer to the BA          | SHH United Kingdom <u>guideline</u> | for the manageme            | ent of Anogen | <u>Ital nerpes</u>  |           |
| Status: Under review              |   |                                     |                             |               |                     |           |
| Gonorrhoea                        |   |                                     |                             |               |                     |           |
| Last updated:<br>June 2023        | For further management guidance please refer to         | the BASHH United Kingdom g          | uideline for the mar        | nagement of ( | <u>Gonorrhoea</u>   |           |
| Status: Under review              |   |                                     |                             |               |                     |           |
| Trichomoniasis                    |   |                                     |                             |               |                     |           |
| Last updated:<br>June 2023        | For management guidance please refer to the BAS         | SHH United Kingdom <u>guideline</u> | on the manageme             | nt of Trichom | ionas vaginalis     |           |
| Status: Under review              |   |                                     |                             |               |                     |           |
| Pelvic<br>inflammatory<br>disease | For further management guidance please refer to disease | the BASHH United Kingdom na         | ational <u>guideline on</u> | the manager   | ment of Pelvic infl | lammatory |
| Last updated:<br>June 2023        |   |                                     |                             |               |                     |           |
| Status: Under review              |   |                                     |                             |               |                     |           |
| ▼ Skin and s                      | oft tissue infections                                   |                                     |                             |               |                     |           |
| Cold sores                        |   |                                     |                             |               |                     |           |
| Last updated:<br>June 2023        | For management guidance please refer to NICE/C          | Clinical Knowledge Summaries:       | Herpes simplex - o          | oral          |                     |           |
| Status: Under review              |   |                                     |                             |               |                     |           |

| Infection                            | Key points  | Medicine  | Doses<br>Adult                  | Child     | Length            | Visual<br>summary |
|--------------------------------------|---|---|---------------------------------|-----------|-------------------|-------------------|
| PVL-SA<br>Last updated:<br>June 2023 | For management guidance please refer to UKHSA   | A (PHE) <u>PVL-Staphylococcus</u>               | aureus infections: dia          | gnosis ar | nd management     |                   |
| Status: Under<br>review              |   |   |                                 |           |                   |                   |
| Eczema<br>(bacterial                 | Manage underlying eczema and flares with treatments such as emollients and topical  | If not systemically unwell, antibiotic          | do not routinely offe           | er either | a topical or oral |                   |
| infection)                           | corticosteroids, whether antibiotics are given or not.  | Topical antibiotic (if a topi only:             | cal is appropriate). F          | or locali | sed infections    |                   |
| NICE                                 | Symptoms and signs of secondary bacterial<br>infection can include: weeping, pustules, crusts,<br>no response to treatment, rapidly worsening<br>eczema, fever and malaise.   | First choice:<br>fusidic acid 2%                | TDS                             |           | 5 to 7 days       |                   |
|                                      | Not all flares are caused by a bacterial infection,   | Oral antibiotic:                                |                                 |           |                   |                   |
| UK Health                            | ealth so will not respond to antibiotics.   | First choice:<br>flucloxacillin                 | 500mg QDS                       |           |                   |                   |
| Security<br>Agency                   | Eczema is often colonised with bacteria but may   | Penicillin allergy or                           | 250mg BD (can be                | 1         |                   |                   |
| 5 7                                  | ncy not be clinically infected.<br>Do not routinely take a skin swab.   | flucloxacillin unsuitable:                      | increased to                    |           |                   |                   |
|                                      | Not systemically unwell:  | clarithromycin <b>OR</b>                        | 500mg BD for severe infections) |           | 5 to 7 days       |                   |
| Last updated:<br>Mar 2021            | Do not routinely offer either a topical or oral antibiotic.   | erythromycin (if macrolide needed in pregnancy; | 250mg to 500mg<br>QDS           | -         |                   |                   |
|                                      | If an antibiotic is offered, when choosing  | consider benefit/harm)                          | QDO                             |           |                   |                   |
|                                      | between a topical or oral antibiotic, take account<br>of patient preferences, extent and severity of<br>symptoms or signs, possible adverse effects,<br>and previous use of topical antibiotics because<br>antimicrobial resistance can develop rapidly with<br>extended or repeated use. |   |                                 |           |                   |                   |
|                                      | Systemically unwell:  | If MRSA suspected or con                        | firmed – consult loca           | al microl | piologist         |                   |
|                                      | Offer an oral antibiotic.   |   |                                 |           |                   |                   |
|                                      | If there are symptoms or signs of cellulitis, see <u>cellulitis and erysipelas</u> .  |   |                                 |           |                   |                   |
|                                      | For detailed information click on the visual summary.   |   |                                 |           |                   |                   |
|                                      |   |   |                                 |           |                   |                   |
|                                      |   |   |                                 |           |                   |                   |

| Infection   | Key points   | Medicine   | Doses<br>Adult                | Child                         | Length  | Visual<br>summary  |
|---|--|--|-------------------------------|-------------------------------|---------|--|
| Impetigo  | Localised non-bullous impetigo:  | Topical antiseptic:                              |                               |                               |         |  |
|   | Hydrogen peroxide 1% cream (other topical antiseptics are available but no evidence for          | hydrogen peroxide 1%                             | BD or TDS                     |                               | 5 days* |  |
|   | impetigo).   | Topical antibiotic:                              |                               |                               |         |  |
| NICE  | If hydrogen peroxide unsuitable or ineffective, short-course topical antibiotic.                 | First choice:<br>fusidic acid 2%                 | TDS                           | tog station by some           |         |  |
| UK Health   | Widespread non-bullous impetigo:   | Fusidic acid resistance                          | TDS                           | Billion Billion               | 5 days* |  |
| Security  | Short-course topical or oral antibiotic.   | suspected or confirmed:                          |                               |                               |         |  |
| Agency  |  | mupirocin 2%                                     |                               |                               |         | Imperigo: antimicrobial prescribing war material   |
|   | topical antibiotics because antimicrobial  | Oral antibiotic:                                 | 500mg QDS                     | 1                             | I.      |  |
| Last updated:   | resistance can develop rapidly with extended or repeated use, and local antimicrobial resistance | First choice:<br>flucloxacillin                  |                               |                               |         | Balance     Image: Second |
| Feb 2020  | data.  | Penicillin allergy or flucloxacillin unsuitable: | 250mg BD                      | for y a fill a Marcing status |         |  |
|   | Bullous impetigo, systemically unwell, or high risk of complications:                            | clarithromycin <b>OR</b>                         |                               |                               | 5 days* |  |
|   | Short-course oral antibiotic.  | erythromycin (if macrolide                       | 250 to 500mg                  |                               |         |  |
|   | Do not offer combination treatment with a topical and oral antibiotic to treat impetigo.         | needed in pregnancy;<br>consider benefit/harm)   | QDS                           |                               |         |  |
|   | For detailed information click on the visual summary.  |  |                               |                               |         |  |
|   | *5 days is appropriate for most, can be increased to 7 days based on clinical judgement.         | If MRSA suspected or con                         |                               |                               |         |  |
| Mastitis  |  |  |                               |                               |         |  |
| Last updated:<br>June 2023                                    | For management guidance please refer to NICE/C   | Clinical Knowledge Summaries                     | s: <u>Mastitis and breast</u> | <u>abscess</u>                |         |  |
| Status: Under review  |  |  |                               |                               |         |  |
| Tick bites<br>(Lyme<br>disease)<br>Last updated:<br>June 2023 | For management guidance please refer to <u>NICE N</u>  | IG95: Lyme disease                               |                               |                               |         |  |
| Status: Under review  |  |  |                               |                               |         |  |

| Infection                               | Key points   | Medicine   | Doses<br>Adult   | Child     | Length     | Visual<br>summary  |
|---|--|--|--|-----------|------------|--|
| Scabies<br>Last updated:<br>June 2023   | For management guidance please refer to the BA   | SHH United Kingdom nationa   | I guideline on the ma  | nagement  | of Scabies |  |
| Status: Under review                    |  |  |  |           |            |  |
| Insect bites<br>and stings              | Most insect bites or stings will not need antibiotics.   |  |  |           |            |  |
| NICE<br>UK Health<br>Security<br>Agency | Do not offer an antibiotic if there are no<br>symptoms or signs of infection.<br>If there are symptoms or signs of infection, see<br><u>cellulitis and erysipelas</u> .<br>For detailed information click on the visual summary. | -  | -  | -         | -          |  |
| Last updated:<br>Sep 2020               |  |  |  |           |            |  |
| Leg ulcer                               | Manage any underlying conditions to promote  | First-choice:  |  | <u> </u>  |            |  |
| infection                               | ulcer healing.   | flucloxacillin   | 500mg to 1g QDS  | -         | 7 days     |  |
|   | Only offer an antibiotic when there are  | Penicillin allergy or if fluc  |  | :         | 1          |  |
| NICE                                    | symptoms or signs of infection (such as redness<br>or swelling spreading beyond the ulcer, localised<br>warmth, increased pain or fever). Few leg ulcers<br>are clinically infected but most are colonised by                    | doxycycline <b>OR</b>  | 200mg on day 1,<br>then 100mg OD<br>(can be increased<br>to 200mg daily) |           |            |  |
| UK Health                               | bacteria.  | clarithromycin <b>OR</b>   | 500mg BD   |           | 7 days     | Lop day Median walkerst a propriet NEE 1993  |
| Security<br>Agency                      | When prescribing antibiotics, take account of severity, risk of complications and previous antibiotic use.   | erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm) | 500mg QDS  |           |            | I water wate |
|   | For detailed information click on the visual summary.  | Second choice:   |  |           |            |  |
| Last updated:<br>Feb 2020               | st updated:  | co-amoxiclav <b>OR</b><br>co-trimoxazole (in<br>penicillin allergy)          | 500/125mg TDS<br>960mg BD  |           | 7 days     |  |
|   |  | For antibiotic choices if s<br>confirmed, click on the vis                   |  | RSA suspe | ected or   |  |

| Infection                  | Koy pointo  | Medicine   | Doses  |  | Longth       | Visual  |  |
|----------------------------|---|--|--|--|--------------|---|--|
| Infection                  | Key points  | Medicine   | Adult  | Child  | Length       | summary   |  |
| Cellulitis and             | Exclude other causes of skin redness  | First choice:  |  |  |              |   |  |
| erysipelas                 | (inflammatory reactions or non-infectious causes).  | flucloxacillin   | 500mg to 1g QDS                                      | Manager of the second s | 5 to 7 days* |   |  |
|                            | Consider marking extent of infection with a   | Penicillin allergy or if fluc  |  |  |              |   |  |
|                            | single-use surgical marker pen.   | clarithromycin <b>OR</b>   | 500mg BD   |  |              |   |  |
| NICE                       | Offer an antibiotic. Take account of severity, site of infection, risk of uncommon pathogens, any         | erythromycin (if macrolide<br>needed in pregnancy;<br>consider benefit/harm) <b>OR</b> | 500mg QDS  |  |              |   |  |
| UK Health                  | microbiological results and MRSA status.  | doxycycline (adults only)  | 200mg on day 1,                                      |  | 5 to 7 days* |   |  |
| Security                   | Infection around eyes or nose is more   | OR   | then 100mg OD  | -  |              | Collection and converted on an interactional proceeding HICE consideration  |  |
| Agency                     | concerning because of serious intracranial complications.   | co-amoxiclav (children<br>only: not in penicillin                                      | -  | Manager of the second s |              | An and a second |  |
|                            | Do not routinely offer antibiotics to prevent   | allergy)   |  | Anna Anna Anna Anna Anna Anna Anna Anna  |              |   |  |
|                            | recurrent cellulitis or erysipelas.   | If infection near eyes or ne   |  |  | •            |   |  |
| Last updated:<br>Sept 2019 | For detailed information click on the visual summary.<br>*A longer course (up to 14 days in total) may be | co-amoxiclav   | 500/125mg TDS  | Manager and an analysis of the second | 7 days*      |   |  |
|                            | needed but skin takes time to return to normal, and   | If infection near eyes or ne   | If infection near eyes or nose (penicillin allergy): |  |              |   |  |
|                            | full resolution at 5 to 7 days is not expected.   | clarithromycin AND   | 500mg BD   | -  |              |   |  |
|                            |   | metronidazole (only add in children if anaerobes                                       | 400mg TDS  | Manager Para   | 7 days*      |   |  |
|                            |   | suspected)   |  |  |              |   |  |
|                            |   | For alternative choice anti confirmed MRSA infection                                   |  |  |              |   |  |

| Infection                       | Kov pointo  | Madiaina  | Doses           |       | Longth  | Visual  |
|---------------------------------|---|---|-----------------|-------|---------|---------|
| Infection                       | Key points  | Medicine  | Adult           | Child | Length  | summary |
| Diabetic foot                   | In diabetes, all foot wounds are likely to be   | Mild infection: first choice  | •               |       |         |         |
| infection                       | colonised with bacteria. Diabetic foot infection  | flucloxacillin  | 500mg to 1g QDS | -     | 7 days* |         |
|                                 | has at least 2 of: local swelling or induration;<br>erythema; local tenderness or pain; local   | Mild infection (penicillin a  | llergy):        | •     |         |         |
|                                 | warmth; purulent discharge.   | clarithromycin OR   | 500mg BD        |       |         |         |
| NICE                            | Severity is classified as:  | erythromycin (if macrolide  | 500mg QDS       |       |         |         |
|                                 | <b>Mild</b> : local infection with 0.5 to less than 2cm erythema  | needed in pregnancy;<br>consider benefit/harm) <b>OR</b>  |                 | _     | 7 days* |         |
| UK Health<br>Security<br>Agency | <b>Moderate</b> : local infection with more than 2cm<br>erythema or involving deeper structures (such<br>as abscess, osteomyelitis, septic arthritis or<br>fasciitis)                           | erythema or involving deeper structures (such<br>as abscess, osteomyelitis, septic arthritis or then 100mg OD<br>(can be increased                |                 |       |         |         |
| Last updated:<br>Oct 2019       | <b>Severe</b> : local infection with signs of a systemic inflammatory response.   | For antibiotic choices for moderate or severe infection, infections where <i>Pseudomonas aeruginosa</i> or MRSA is suspected or confirmed, and IV |                 |       |         |         |
|                                 | Start antibiotic treatment as soon as possible.   | antibiotics click on the vis  |                 |       |         |         |
|                                 | Take samples for microbiological testing before,<br>or as close as possible to, the start of treatment  |   |                 |       |         |         |
|                                 | When choosing an antibiotic, take account of severity, risk of complications, previous microbiological results and antibiotic use, and patient preference.                                      |   |                 |       |         |         |
|                                 | *A longer course (up to a further 7 days) may be<br>needed based on clinical assessment. However, skin<br>does take time to return to normal, and full resolution<br>at 7 days is not expected. |   |                 |       |         |         |
|                                 | Do not offer antibiotics to prevent diabetic foot infection.  |   |                 |       |         |         |
|                                 | For detailed information click on the visual summary.   |   |                 |       |         |         |

| Infection                 | Key points   | Medicine   | Doses  |                     | Length   | Visual  |
|---------------------------|--|--|--|---------------------|----------|---|
| Intection                 |  | Medicine   | Adult  | Child               | Lengin   | summary                                       |
| Acne vulgaris             | <b>First-line treatment options</b> : offer a course of 1 of the options, taking account of severity, preferences, and advantages/disadvantages of each option. Completing the course is important because positive effects can take 6 to 8 weeks. Consider topical benzoyl peroxide monotherapy as an alternative if first-line treatment options | <b>First line</b> : fixed<br>combination of topical<br>adapalene with topical<br>benzoyl peroxide (for any<br>acne severity, not in under<br>9s) <b>OR</b>   | 0.1% adapalene/<br>2.5% benzoyl<br>peroxide <b>OR</b> 0.3%<br>adapalene/2.5%<br>benzoyl peroxide<br>OD (thinly<br>evening)   | BNF<br>for children |          |   |
| Last updated:<br>Jun 2021 | are contraindicated, or to avoid topical retinoids<br>or an antibiotic (topical or oral).<br><b>Do not use</b> : monotherapy with a topical<br>antibiotic, monotherapy with an oral antibiotic, or<br>a combination of a topical antibiotic and an oral  | fixed combination of<br>topical tretinoin with topical<br>clindamycin (for any acne<br>severity, not in under 12s)<br><b>OR</b>  | 0.025% tretinoin/<br>1% clindamycin<br>OD (thinly in the<br>evening)   | BNF<br>for children |          |   |
|                           | <ul> <li>antibiotic.</li> <li>Review first-line treatment at 12 weeks.</li> <li>Only continue a topical or oral antibiotic for more than 6 months in exceptional circumstances.</li> <li>Review at 3 monthly intervals, and stop the antibiotic as soon as possible.</li> <li>For detailed information see the NICE guideline on</li> </ul>        | fixed combination of<br>topical benzoyl peroxide<br>with topical clindamycin<br>(for mild to moderate acne,<br>not in under 12s) <b>OR</b>   | 3% benzoyl<br>peroxide/1%<br>clindamycin <b>OR</b><br>5% benzoyl<br>peroxide/1%<br>clindamycin OD (in<br>the evening)  | BNF<br>for children | 12 weeks | Not available.<br>See the <u>NICE</u>         |
|                           | <u>acne vulgaris</u> .   | fixed combination of<br>topical adapalene with<br>topical benzoyl peroxide<br><b>AND</b> either oral<br>lymecycline or oral<br>doxycycline (for moderate<br>to severe acne, not in<br>under 12s) <b>OR</b> | 0.1% adapalene/<br>2.5% benzoyl<br>peroxide <b>OR</b> 0.3%<br>adapalene/2.5%<br>benzoyl peroxide<br>OD (in the<br>evening)<br><b>AND</b><br>lymecycline 408mg<br>OD<br><b>OR</b> | BNF<br>for children |          | <u>guideline on</u><br><u>acne vulgaris</u> . |
|                           |  |  | doxycycline 100mg<br>OD  | BMF<br>for children |          |   |

| Infection   | Key points                                    | Medicine  | Doses   |   | Length   | Visual  |
|---|---|---|---|---|----------|---------|
| Incetion  |   | topical azelaic acid <b>AND</b><br>either oral lymecycline or<br>oral doxycycline (for<br>moderate to severe acne,<br>not in under 12s) | Adult<br>15% or 20%<br>azelaic acid BD<br>AND<br>lymecycline 408mg<br>OD<br>OR<br>doxycycline 100mg<br>OD | Child<br>BNF<br>for children<br>BNF<br>for children | Length   | summary |
|   |   | Alternative: topical benzoyl peroxide   | 5% benzoyl peroxide OD to BD  | BNF<br>for children                                 |          |         |
| Dermatophyte<br>infection: skin<br>Last updated:<br>June 2023 | For management guidance please refer to NICE/ | Clinical Knowledge Summaries  | s: <u>Fungal skin infectior</u>   | n - body a  | nd groin |         |
| Status: Under review  |   |   |   |   |          |         |
| Dermatophyte<br>infection: nail<br>Last updated:<br>June 2023 | For management guidance please refer to NICE/ | Clinical Knowledge Summarie   | s: Fungal nail infection  |   |          |         |
| Status: Under<br>review                                       |   |   |   |   |          |         |

| Infection          | Key points  | Medicine                      | Doses<br>Adult                | Child  | Length  | Visual<br>summary   |
|--------------------|---|-------------------------------|-------------------------------|--|---|---|
| Human and          | Offer an antibiotic for a human or animal bite if   | First choice:                 | Addit                         | Onna   |   | Summary   |
| animal bites       | there are symptoms or signs of infection, such<br>as increased pain, inflammation, fever,<br>discharge or an unpleasant smell. Take a swab<br>for microbiological testing if there is discharge<br>(purulent or non-purulent) from the wound. | co-amoxiclav                  | 250/125mg or<br>500/125mg TDS |  | 3 days for<br>prophylaxis<br>5 days for<br>treatment* |   |
|                    | Do not offer antibiotic prophylaxis if a human or   | Penicillin allergy or co-an   | noxiclav unsuitable:          |  |   | -   |
|                    | animal bite has not broken the skin.  | doxycycline AND               | 200mg on day 1,               |  | 2 dove for  |   |
| UK Health          | Human bite:   |                               | then 100mg or 200mg daily     | Angel Free days<br>Description<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Participation<br>Partic | 3 days for<br>prophylaxis                             |   |
| Security<br>Agency | Offer antibiotic prophylaxis if the human bite has broken the skin and drawn blood.   | metronidazole                 | 400mg TDS                     |  | 5 days for<br>treatment*                              |   |
|                    | Consider antibiotic prophylaxis if the human bite   | seek specialist advice in     | pregnancy                     |  | liealment   |   |
| Last updated:      | has broken the skin but not drawn blood if it is in<br>a high-risk area or person at high risk.   | IV antibiotics (click on visu | ial summary)                  |  |   |   |
| Nov 2020           | Cat bite:   |                               |                               |  |   |   |
|                    | Offer antibiotic prophylaxis if the cat bite has broken the skin and drawn blood.   |                               |                               |  |   | Next relation to activity of produce<br>There is a state of a state |
|                    | Consider antibiotic prophylaxis if the cat bite has<br>broken the skin but not drawn blood if the wound<br>could be deep.   |                               |                               |  |   |   |
|                    | Dog or other traditional pet bite (excluding cat bite)  |                               |                               |  |   |   |
|                    | Do not offer antibiotic prophylaxis if the bite has broken the skin but not drawn blood.  |                               |                               |  |   |   |
|                    | Offer antibiotic prophylaxis if the bite has broken<br>the skin and drawn blood if it has caused<br>considerable, deep tissue damage or is visibly<br>contaminated (for example, with dirt or a tooth).                                       |                               |                               |  |   |   |
|                    | Consider antibiotic prophylaxis if the bite has<br>broken the skin and drawn blood if it is in a high-<br>risk area or person at high risk.   |                               |                               |  |   |   |
|                    | For detailed information click on the visual summary.<br>*course length can be increased to 7 days (with<br>review) based on clinical assessment of the wound.  |                               |                               |  |   |   |
|                    |   |                               |                               |  |   |   |

| Infontion  | Kay pointa  | Medicine                    | Doses                | Doses         |                   | Visual        |
|--|---|-----------------------------|----------------------|---------------|-------------------|---------------|
| Infection  | Key points  | Medicine                    | Adult                | Child         | Length            | summary       |
| Varicella<br>zoster/<br>chickenpox                       | For management guidance please refer to NICE/C<br>Or  | linical Knowledge Summaries | - <u>Chickenpox</u>  |               |                   |               |
| Herpes zoster/<br>shingles<br>Last updated:<br>June 2023 | NICE/Clinical Knowledge Summaries - <u>Shingles</u>   |                             |                      |               |                   |               |
| Status: Under<br>review                                  |   |                             |                      |               |                   |               |
| Eye infect   | ions  |                             |                      |               |                   |               |
| Conjunctivitis<br>Last updated:                          | For management guidance please refer to NICE/C  | linical Knowladga Summarias |                      | octivo        |                   |               |
| June 2023  | For management guidance please reler to MICE/C  | inical Knowledge Summanes.  |                      | ective        |                   |               |
| Status: Under review                                     |   |                             |                      |               |                   |               |
| Blepharitis<br>Last updated:<br>June 2023                | For management guidance please refer to NICE/C  | linical Knowledge Summaries | : <u>Blepharitis</u> |               |                   |               |
| Status: Under review                                     |   |                             |                      |               |                   |               |
|  | I dental infections in primary care (outside d  |                             |                      |               |                   |               |
| care services wit  | not designed to be a definitive guide to oral conditior<br>h dental problems should be directed to their regular<br>of how to access emergency dental care. |                             |                      |               |                   |               |
|  | mation on this topic please refer to the: College c<br>crobial Prescribing in Dentistry: Good Practice Guide  |                             | Ity of Dental Surger | y (FDS) of th | e Royal College o | f Surgeons of |
| Abbreviati   | ons   |                             |                      |               |                   |               |
|  | eGFR, estimated glomerular filtration rate; IM, intram<br>MRSA, methicillin-resistant <i>Staphylococcus aureus</i><br>s a day.                              |                             |                      |               |                   |               |